The general coordinator of the Ministry of Health Pharmaceutical and Strategic Medicine Department, Lorena Evangelista, sent the answer to the petition on the transference of the Hepatitis C medicines from the “specific” category to the “strategic” one as requested by the FOAESP**.
According to the general coordinator letter, “the Specialized Component is responsible for programming consumption estimates, acquisition, financing, storage management and distribution of the Hepatitis C drugs”. In the FOAESP’s opinion, that “is resulting on delays in medicine delivery, as well as rampering the access of the eligible patients to the treatment besides obstructing the access to the resources invested on the purchase of those medicines”.
Check the letter below:
Official Letter n° 120/2018/CGAFME/DAF/SCTIE/MS
Addressed to: Mr. Rodrigo Pinheiro
PRESIDENT OF THE STATE OF SÃO PAULO FORUM ON NGO/AIDS - FOAESP
Subject matter: Transference of the Hepatitis C medicines to the Strategic Component Department of the Pharmaceutical Assistance
Honourable Mr. Pinheiro,
The document addresses the Official Letter sent by the President of the State of São Paulo Forum on NGO/AIDS, expressing the group will of moving the medicines used on the treatment of Hepatitis C to the Strategic Component of the Pharmaceutical Assistance – CESAF.
According to the Ordinance n. 2, dated on September 28, 2017, on the SUS national health policies standards and the Ordinance n. 6, also dated on September 28, 2017, which regulates the funds and transference of national resources to heath actions and services headed by the Brazilian Unified System, SUS, the Specialized Component is responsible for programming, purchasing, financing, stock managing and distribution of Hepatitis C medicines. Besides that, it is its responsibility all the steps of ordering, evaluating, authorizing, distributing and enrolling people to continue treatment, as all the medicines that are part of the Specialized Component 1A Group, which the purchase and provision to the State Health Departments and the Federal District are the Ministry of Health prerogative.
Due to the national plan on eliminating Hepatitis C until 2030, announced by the honorable Minister of Health, we inform that the Ministry of Health members are considering developments, changes on the Clinical Protocol and Guidelines and the competence of drug control for the treatment of Hepatitis C.
Transferring the responsibility of those medicines to CESAF will demand internal rearrangements, changes in law, new agreements, reorganizing the system and set new criteria to control stock and distribution.
LORENA BRITO EVANGELISTA
Coordinator - CGAFME/DAF/SCTIE/MS
RENATO ALVES TEIXEIRA LIMA
Chairman - DAF/SCTIE/MS